

20年続く医薬南米プラン





20

この会社はコロンビアで19年の実績があり、INVIMAの登録も持っています。

グアテマラや中米5カ国への市場拡大のため、1つの大きな代理店と真剣に話し合っています。コロンビアの全主要都市と多くの副都市に289の提携薬局があります。CRMは非常によく組織化されており、医師、薬局、機関投資家の間で1397人の会員がいる。コロンビアの全主要都市と多くの副都市に289の提携薬局があります。

商業市場

- 売上の75%は医師経由
- 売上の25%は機関投資家向け

原薬、賦形剤、包装、製品を購入し、すべてINVIMAに認可されたコロンビア国内の専門工場に委託して製造しています。

現在、INVIMAと商工総局に登録・認可されている製品は32品目。今後、新たに2製品がINVIMAから承認される予定です。

コロンビアのINVIMAによる認可には平均2年、3万米ドルの投資が必要です。

このビジネスには5つの栄養製品があり、私たちはそのうちのブランドを所有していますが、登録はしていません。

製品情報

抗生物質

- 鎮痛剤
- 抗炎症剤
- 抗ヒスタミン剤
- 循環器
- 栄養補助食品
- 消化器系
- 脂質低下剤
- 小児用製品。抗生物質と栄養剤

TARGET PRICE

\$11,500,000

GROSS REVENUE

\$2,000,000

EBITDA

\$450,000

BUSINESS TYPE

製造業

ESTABLISHED

2002-06-22

SUPPORT & TRAINING

6ヶ月

REASON FOR SELLING

退任

COUNTRY

コロンビア

BUSINESS ID

L#20210109

The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction.

The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.

By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.

This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.

The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.

All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.

www.mergerscorp.com



WWW.MERGERSCORP.COM